Increased sensitivity to the bcl-2 inhibitor venetoclax was found in a subgroup of MCL lines with high BCL2 expression (Maver-1, Mino, HBL-2)27–29, a subgroup of BCL-2 dependent lymphoma lines (OCI-LY-1 and OCI-LY-8)30–32, a BL cell line (DOGKIT) known to harbour BCL2 rearrangements33 and the B-NHL line Granta-519, which has been shown to overexpress BCL234 (Figs 2A, S2). The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.